Two studies indicate that higher doses of psilocybin are necessary for sustained reductions in depression and anxiety.
Research is indicating that a less efficient metabolic pathway plays a role in DMT’s psychoactivity.
A double-blind study reveals that mindfulness meditation practice may amplify the positive effects of psilocybin while reducing the likelihood of a bad trip.
The new REBUS model helps explain the subjective and neurochemical effects of psychedelics on the brain.
The catalog of compounds for use in psychedelic drug research continues to grow.
The researchers hope these compounds “will expand the universe of options for improving mental health.”
With the paradigm shift created by psychedelics, a recent study suggests reconsidering the medical model of mental illness.
Scientific research does not support his statements that psychedelics are “very potent” and “very dangerous.”
Comments from Matthew Johnson of Johns Hopkins provide an update on this research.
Three clinical trials are underway to find out if these psychedelic compounds can provide relief for patients.